Drug Trial Radar · NCT00880308
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Mar 2009
Primary completion
Jul 2013
Study completion Jul 2013
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 13, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor Cancers
- Medulloblastoma
- Basal Cell Carcinoma
Interventions
LDE225Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- determine maximum tolerated dose of single agent LDE225Time frame: 28 day cycles
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
University of Pittsburgh Medical Center SC
Pittsburgh, Pennsylvania
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
San Antonio, Texas
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Leicester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.